Cargando…
Drug Repurposing Approaches to Combating Viral Infections
Development of novel antiviral molecules from the beginning costs an average of $350 million to $2 billion per drug, and the journey from the laboratory to the clinic takes about 10–15 years. Utilization of drug repurposing approaches has generated substantial interest in order to overcome these dra...
Autores principales: | Trivedi, Jay, Mohan, Mahesh, Byrareddy, Siddappa N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700377/ https://www.ncbi.nlm.nih.gov/pubmed/33238464 http://dx.doi.org/10.3390/jcm9113777 |
Ejemplares similares
-
Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19
por: Husain, Amjad, et al.
Publicado: (2020) -
SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?
por: Byrareddy, Siddappa N., et al.
Publicado: (2020) -
Combining antiviral drugs with BET inhibitors is beneficial in combatting SARS‐CoV‐2 infection
por: Acharya, Arpan, et al.
Publicado: (2022) -
Long Term Delta-9-tetrahydrocannabinol Administration Inhibits Proinflammatory Responses in Minor Salivary Glands of Chronically Simian Immunodeficieny Virus Infected Rhesus Macaques
por: Alvarez, Xavier, et al.
Publicado: (2020) -
Repurposing Immunomodulatory Drugs to Combat Tuberculosis
por: Fatima, Samreen, et al.
Publicado: (2021)